L-alpha-2A L-cells (ATCC® CRL-11180)

Organism: Mus musculus, mouse  / 

Organism Mus musculus, mouse
Product Format frozen
Morphology fibroblast
Culture Properties adherent, single cells and loosely attached clusters
Biosafety Level 1
Age 100 days
Gender male
Strain C3H/An
Storage Conditions liquid nitrogen vapor phase
Images
Derivation
This line is a derivative of L-M(TK-) (see ATCC CCL-1.3) that is stably transfected with the gene for the human adrenergic alpha2A receptor.
Clinical Data
male
Receptor Expression
human adrenergic alpha2A, expressed
Comments
This line is a derivative of L-M(TK-) (see ATCC CCL-1.3) that is stably transfected with the gene for the human adrenergic alpha2A receptor.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Protocol:
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
  3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended
Medium Renewal: Two to three times weekly
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Name of Depositor Synaptic Pharmaceutical Corporation
References

Gluchowski C, et al. Use of alpha1C specific compounds to treat benign prostatic hyperplasia. US Patent 5,403,847 dated Apr 4 1995

Lagu B, et al. Morpholinone and morpholine derivatives and uses thereof. US Patent 6,531,471 dated Mar 11 2003

Gluchowski C, et al. Use of .alpha.1C specific compounds to treat benign prostatic hyperplasia. US Patent 6,602,888 dated Aug 5 2003

Cui D, et al. Dihydropyrimidines and uses thereof . U.S. Patent 6,680,323 dated Jan 20 2004

Basic Documentation
Other Documentation
References

Gluchowski C, et al. Use of alpha1C specific compounds to treat benign prostatic hyperplasia. US Patent 5,403,847 dated Apr 4 1995

Lagu B, et al. Morpholinone and morpholine derivatives and uses thereof. US Patent 6,531,471 dated Mar 11 2003

Gluchowski C, et al. Use of .alpha.1C specific compounds to treat benign prostatic hyperplasia. US Patent 6,602,888 dated Aug 5 2003

Cui D, et al. Dihydropyrimidines and uses thereof . U.S. Patent 6,680,323 dated Jan 20 2004